

EU4H-2024-PJ-01-4 (CP-g-24-105) Call for proposals to support the development of novel antivirals (HERA)

Objective

- to be better prepared to respond to serious cross-border health threats
- to contribute to the achievement of the EU4Health Programme's general objective of protecting people in the Union from serious cross-border threats to health
- To strengthen the responsiveness of health systems and coordination among the Member States to cope with serious cross-border threats to health

Scope (1)

- to diversify and advance the pipeline of broad-spectrum antivirals candidates
- to support the development and further characterisation of broad-spectrum antivirals targeting identified HERA priority viral families:
 - respiratory RNA viral families
 - viral families known for causing viral haemorrhagic fever
- to advance clinical development of a potent candidate

Scope (2)

- Complementarity with existing Horizon Europe projects
- Early safety and efficacy trials for testing new or improved anti-viral therapeutics
- When possible, innovative delivery systems and suitable safety profiles for broad use
- application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics

Specific mandatory deliverables and/or milestones (1)

- Details of the studies and tests supported (including efficacy testing in animal and/or human challenge models)
- Ethical approvals for testing and/or clinical protocols.
- When applicable, patient enrolment plan and implementation, ensuring that those trials are preferably carried out in the EU.

Specific mandatory deliverables and/or milestones (1)

- Testing and trial results including those towards the establishment of maximum tolerated dose, dose ranging, adverse effects, pharmacokinetics and pharmacodynamics.
- documentation resulting from engagement with regulatory bodies: applicants are expected to engage with regulatory bodies in a timely manner to ensure adequacy of the actions from a regulatory point of view.

Expected Impact

- to bring innovative, emerging, and cutting-edge elements with significant economic potential to the internal market or
- to reduce or prevent strategic dependencies of the Union

Special requirements

- Applicants – specific eligibility criteria:
 - Private, academic and public bodies active and in the field of innovation and with proven expertise in drug development of antivirals.
- Specific eligibility criteria applicable to the consortium composition:
 - Applications may be submitted either by a single applicant or a consortium of at least 3 applicants (beneficiaries; not affiliated entities).